Pro Medicus Ltd (ASX: PME) shares are clawing back some lost ground, rising 3% to $182.33. But that bounce barely dents a brutal decline of 12% over the past month and 41% over 12 months.
For a business with Pro Medicus' track record, that sort of sell-off is hard to ignore. But is the discount genuine, or is the market warning investors about something?
Image source: Getty Images
The business hasn't suddenly broken
Pro Medicus is a healthcare informatics company providing medical imaging software to hospitals, imaging centres and healthcare groups.
And here's the interesting bit: its underlying demand drivers haven't disappeared. Hospitals are still generating enormous volumes of medical scans, while radiologists need increasingly sophisticated technology to access and interpret those images.
That's where Pro Medicus' Visage software comes in. The platform is designed to help clinical teams access medical images quickly across large health networks, giving Pro Medicus shares a powerful competitive position.
The numbers are still doing the talking
Pro Medicus delivered another cracking first half of FY26. Revenue climbed 28.4% to $124.8 million, while underlying profit before tax jumped 29.7% to $90.7 million. Even better, EBIT margins expanded from 72% to 73%.
Reported net profit surged more than 230%, although investors shouldn't get too excited about that headline number because much of the increase came from an unrealised gain on its investment in 4D Medical Ltd (ASX: 4DX).
The more important numbers are arguably sitting on the balance sheet. Pro Medicus finished the half with $221.8 million in cash and investments, and no debt.
There's plenty more runway
The US remains a massive opportunity for Pro Medicus shares. The company secured seven new contracts worth more than $280 million at minimum volumes during the first half, including a major agreement with University of Colorado Health.
The company's transaction-based model is particularly attractive because revenue can grow as examination volumes increase, even after a hospital has signed up.
And Pro Medicus isn't stopping at radiology. Visage is expanding into cardiology, while management continues working on artificial intelligence and solutions for other medical specialties.
An Ohio State renewal, for example, expanded its relationship to include Visage 7 Workflow and Cardiology Imaging.
So, is the healthcare tech stock a buy?
That's the million-dollar question. The quality of the business is difficult to dispute. Strong margins, a debt-free balance sheet, recurring contract wins and significant US growth opportunities make Pro Medicus an intriguing long-term story.
But there's a catch. Even after the sell-off, the valuation demands continued execution. If growth slows materially, investors could discover that the shares weren't as cheap as they looked.
Pro Medicus reports its FY26 results on 18 August. That result could be the next big test of whether beaten-down Pro Medicus shares represent a genuine opportunity. Or is it simply a stock that still has further to fall.
